Here are some of the largest recent moves: LPL FINANCIAL LLC added 158,405 shares (+301.0%) to their portfolio in Q4 2024, for an estimated $2,776,839 CAPITAL MANAGEMENT CORP /VA removed 118,345 shares (-28.2%) from their portfolio in Q4 2024, for an estimated $2,074,587 ENVESTNET ASSET MANAGEMENT INC removed 76,629 shares (-34.4%) from their portfolio in Q4 2024, for an estimated $1,343,306 SUSQUEHANNA INTERNATIONAL GROUP, LLP added 71,979 shares (+128.3%) to their portfolio in Q4 2024, for an estimated $1,261,791 EAM INVESTORS, LLC added 60,243 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,056,059 683 CAPITAL MANAGEMENT, LLC added 49,500 shares (+inf%) to their portfolio in Q4 2024, for an estimated $867,735 RENAISSANCE TECHNOLOGIES LLC removed 47,300 shares (-5.7%) from their portfolio in Q4 2024, for an estimated $829,169 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard
A spokesperson for Novo Nordisk described the compounding system as not working as intended. Novo Nordisk will continue to take legal action against compounding pharmacies and other entities engaged in unlawful marketing and sales of unapproved compounded semaglutide drugs, the spokesperson said
The trial team will assess the exposure against the IMP label and protocol and advise whether the medicine remains suitable for use
Changes can also reflect shifts in hydration, inflammation, nutrition status, mobility, comorbidities, or concurrent medications
Zepbound (tirzepatide) is FDA approved for weight loss and obstructive sleep apnea
Maintenance planning Clear discussion about how to maintain results if the medication is reduced or discontinued, with emphasis on sustainable habits and metabolic health, not just the number on the scale
